[SCHEDULE 13G] SpringWorks Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Resources Connection, Inc. (Nasdaq: RGP) entered into a new secured revolving Credit Facility with Bank of America on 2 July 2025. The agreement replaces the 2021 facility and offers:

• Commitment: up to the lesser of $50 million and a receivables-based borrowing base, plus an $15 million accordion option.
• Maturity: 30 November 2029 – extending the company’s debt horizon by nearly four years versus the prior line.
• Pricing: borrower election of Term SOFR + 1.25%–2.50% or Base Rate + 0.25%–1.50%, scaled to consolidated EBITDA; includes customary commitment and letter-of-credit fees (LC sub-limit: $10 million).
• Collateral: substantially all assets of the parent, Resources Connection LLC and domestic subs under a new Security and Pledge Agreement.
• Use of proceeds: working capital, general corporate purposes, acquisitions, and full repayment/termination of the 2021 Credit Agreement.
• Covenants & defaults: limits on liens, additional debt, restricted payments, M&A, and asset sales; maintenance tests for net leverage and fixed-charge coverage. Standard acceleration and cross-default provisions apply.

The facility increases liquidity headroom, lengthens tenor and aligns borrowing costs with market rates, but introduces asset security and tighter covenant discipline.

Insights

Senior Credit Analyst

TL;DR – New $50 m revolver lengthens tenor and boosts liquidity; covenant package introduces discipline but seems manageable.

The five-year secured revolver removes near-term refinancing risk, pushing maturity to 2029 and adding an accordion that could lift availability to $65 m if conditions warrant. Pricing at SOFR +1.25-2.50% is broadly in line with upper-BB/split-BBB middle-market benchmarks; the leverage-based grid rewards deleveraging. Collateralization of substantially all assets improves lender protection but signals modest tightening of credit terms versus the prior unsecured line. Financial covenants (net leverage and FCCR) look standard and should be serviceable given RGP’s historically low leverage profile. Overall impact skews positive: liquidity improves, strategic flexibility expands for bolt-on acquisitions, and refinancing uncertainty is removed.

Equity Research Analyst – Professional Services

TL;DR – Facility ups liquidity for growth, but secured stance could slightly raise balance-sheet risk if end markets soften.

Operationally, the revolver gives management headroom to fund working-capital swings and tuck-in deals, both vital in a project-based consulting model. The extended maturity reduces covenant-driven cash hoarding, supporting potential shareholder returns should free cash flow allow. However, the blanket lien limits future unencumbered borrowing capacity and exposes assets if macro conditions deteriorate. No immediate earnings effect appears, yet incremental interest expense could rise if rates remain elevated. Net, I view the filing as moderately positive for strategic optionality without materially altering the equity thesis.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

SpringWorks Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

85205L107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 85205L107

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 85205L107

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.00 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SpringWorks Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 100 Washington Blvd, Stamford, Connecticut 06902
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 85205L107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0.00
(b)	Percent of class: 0.00 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons may have been deemed to beneficially own more than 5% of the outstanding shares on the date of event that required the filing of the Schedule 13G. As of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	07/07/2025

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	07/07/2025

FAQ

What is the size of Resources Connection's new credit facility?

The revolver is available up to the lesser of $50 million and a receivables-based borrowing base, with an additional $15 million accordion option.

When does the new RGP credit facility mature?

The facility matures on 30 November 2029.

What interest rates will RGP pay under the facility?

Borrowings bear Term SOFR +1.25%–2.50% or Base Rate +0.25%–1.50%, depending on consolidated EBITDA.

Why did RGP terminate its 2021 Credit Agreement?

The 2021 facility was fully refinanced and terminated on 2 July 2025 in conjunction with entering the new agreement.

What can RGP use the new credit facility for?

Permitted uses include working capital, general corporate purposes, acquisitions, and refinancing prior debt.